TABLE 3.

Summary of cefepime pharmacokinetic parameters for patients receiving CVVH

Patient	Dosing regimen	Cmax (μg/ml)	Cmin (μg/ml)	AUC0–24 (μg · h/ml)	t1/2 (h)	V (liter/kg)	CLS		UFRa (ml/min)	CRRT CLb			Sb
							ml/min	ml/min/kg		ml/min	ml/min/kg	%CLS
1	2 g every 24 h	61.6	18.7	943.5	13.7	0.64	38 ± 6	0.54 ± 0.08	19 ± 2	16 ± 4	0.23 ± 0.05	42 ± 3	0.92 ± 0.07
2	2 g every 24 h	67.4	13.5	1,050.9	10.2	0.36	44 ± 4	0.41 ± 0.04	9 ± 8	3 ± 2	0.03 ± 0.02	8 ± 4	0.84 ± 0.05
3	2 g every 24 h	86.4	20.7	1,258.4	11.4	0.38	33 ± 4	0.38 ± 0.04	19 ± 4	17 ± 3	0.19 ± 0.04	29 ± 19	0.89 ± 0.08
4	1 g every 12 h	44.6	27.9	834.7	17.0	0.43	28 ± 3	0.29 ± 0.03	15 ± 2	13 ± 3	0.13 ± 0.03	45 ± 14	0.81 ± 0.13
5	2 g every 12 h	94.9	48.0	1,677.8	12.2	0.38	35 ± 1	0.36 ± 0.01	17 ± 12	14 ± 10	0.14 ± 0.10	39 ± 28	0.83 ± 0.11
Mean ± SD					12.9 ± 2.6	0.46 ± 0.14	36 ± 6c	0.40 ± 0.09c	16 ± 4a	13 ± 4a	0.15 ± 0.06c	40 ± 16c	0.86 ± 0.04c

^aUFR, ultrafiltration rate. 

^bValues are means ± standard deviations calculated from parameter values determined during each of the four or five postdose sampling intervals for each patient: 1 to 2 h, 2 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h (except with 12-h dosing interval regimens). 

^cMeans ± standard deviations calculated from means of the four or five parameter values determined for each individual patient.